Search clinical trials for: 12.5 mg empagliflozin/850 mg metformin FDC

Total 3102 results

Novartis Pharmaceuticals

Terminated

Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment

Asthma

Germany, United States, Belgium, India, Poland, Romania, Estonia, Japan, Turkey, Singapore, Australia, Israel, Netherlands, Russian Federation, Spain, Canada, Lebanon, France, Greece, Slovakia, Austria, United Kingdom, Czechia, Latvia, ... and more
Bandim Health Project

Completed

Effectiveness and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for Treating Malaria

Malaria | Effectiveness

Guinea-Bissau
Mitsubishi Tanabe Pharma Corporation

Completed

Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia

Schizophrenia

Japan
Boehringer Ingelheim

Completed

Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy

Hypertension

Japan
Pfizer

Completed

A Target Occupancy Study With Ritlecitinib.

Healthy

United States
Repros Therapeutics Inc.

Terminated

Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids

Uterine Fibroids

United States
Vanda Pharmaceuticals

Completed

VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

Insomnia

United States
Peptron, Inc.

Active, not recruiting

SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease

Early Parkinson's Disease

Korea, Republic of
The Cleveland Clinic
Bristol-Myers Squibb; National Institute of Allergy and Infectious Diseases... and other collaborators

Terminated

Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression

HIV Infection | Mitochondrial Dysfunction

United States
Idorsia Pharmaceuticals Ltd.

Completed

Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949

Healthy Subjects

Netherlands
Corcept Therapeutics

Completed

Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants

Healthy

United Kingdom
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Withdrawn

NT-814: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in an Exploratory Clinical Study (NT-814)

Opioid Use Disorder

United States
Ferring Pharmaceuticals

Completed

A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy

Prostate Cancer

United States, Netherlands, Hungary, Czech Republic, Germany, Mexico, Romania, Russian Federation, Ukraine, Canada, Puerto Rico, United Kingdom
GlaxoSmithKline

Completed

Study to Determine the Bioequivalence of Two Fixed Dose Combination (FDC) Tablet Formulations of Amlodipine and Losartan FDC5/50 and FDC5/100 Under Fasting Conditions

Hypertension

South Africa
Darnitsa Pharmaceutical Company
International Pharmaceutical Research Center

Completed

Bioequivalence Study of 8 mg Perindopril Tert-butylamine / 2.5 mg Indapamide Tablets Versus 10 mg Perindopril Arginine / 2.5 mg Indapamide Film-coated Tablets in Healthy Volunteers

Healthy Subjects | Bioequivalence

Jordan
Amsterdam UMC, location VUmc

Recruiting

Empagliflozin in Pulmonary Arterial Hypertension (Emphower PoC)

Idiopathic Pulmonary Arterial Hypertension

Netherlands
University of Texas Southwestern Medical Center
Boehringer Ingelheim

Completed

Impact of Empagliflozin on Functional Capacity in Heart Failure With Preserved Ejection Fraction

Diabetes Mellitus | Heart Failure, Diastolic | Heart Failure With Preserved Ejection Fraction

United States
Zhijun Sun

Enrolling by invitation

Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Heart Failure | Heart Failure With Preserved Ejection Fraction | Heart Failure With Mid Range Ejection Fraction

China
Isfahan University of Medical Sciences

Completed

Antiischemic Effects of Empagliflozin in Diabetic Patients With Refractory Angina

Diabetes Mellitus

Iran, Islamic Republic of
vTv Therapeutics

Not yet recruiting

Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes (CATT1)

Diabetes Mellitus, Type 1
GlaxoSmithKline

Completed

A Two Cohort Study to Look at the Metabolites of GSK221149, the Metabolism of GSK221149 Administered With a High Fat Meal and With Ketoconazole

Obstetric Labour, Premature

United States
Medicines for Malaria Venture
Q-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer...

Completed

Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A

Malaria

Australia
Juntendo University
Boehringer Ingelheim

Recruiting

Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure (EMPA-AHF)

Acute Heart Failure

Japan
Jacob Moller
Rigshospitalet, Denmark; University Hospital Bispebjerg and Frederiksberg; Hillerod... and other collaborators

Recruiting

The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure

Heart Failure | Obesity

Denmark
University Hospital Inselspital, Berne
Boehringer Ingelheim; University of Bern

Completed

Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers (SWEETSTONE)

Kidney Stone

Switzerland
National Institute on Aging (NIA)

Completed

Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production

Physiological Effects of Drugs | Hypoglycemic Agents | Empaglifozin | Sodium-Glucose Transporter 2 Inhibitors

United States
Mario Negri Institute for Pharmacological Research
Boehringer Ingelheim

Withdrawn

SGLT2 Inhibitors in Glomerular Hyperfiltration (EMPATHY)

Obesity | Non-diabetic Chronic Kidney Disease
Cancer Institute and Hospital, Chinese Academy...
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR

Lung Adenocarcinoma
Shire

Completed

Safety and Efficacy of NPS 1776 in the Acute Treatment of Migraine Headaches

Migraine Headache

United States
University Health Network, Toronto

Recruiting

The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients (HALLMARK)

Kidney Transplant Recipients

Canada
MedImmune LLC

Completed

A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants (MEDI8897 1b)

Respiratory Syncytial Virus

United States, South Africa, Chile
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis

Type 1 Diabetes | Type 2 Diabetes

United States
Chinese PLA General Hospital

Completed

Low Dose Ruxolitinib in Combination With Methylprednisolone

Stem Cell Transplant Complications | aGVHD

China
University of Catanzaro

Completed

Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study) (FIORE)

Type 2 Diabetes | Cardiovascular Risk Factor

Italy
Ain Shams University

Not yet recruiting

Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin

Cancer
Alexandria University

Recruiting

Effect of Empagliflozin on NT-Pro Brain Natriuretic Peptide in Heart Failure Patients With Reduced Ejection Fraction

Heart Failure With Reduced Ejection Fraction

Egypt
Maria Sklodowska-Curie National Research Institute...
Medical Research Agency, Poland

Recruiting

Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines (EMPACT)

Cardiotoxicity

Poland
National Institute of Cardiology, Warsaw, Poland
Amsterdam UMC, location VUmc; University of Eastern Finland; Medical University...

Recruiting

Empagliflozin in Hypertrophic Cardiomyopathy (EMPA-REPAIR)

Heart Failure | Hypertrophic Cardiomyopathy

Poland
NHS Greater Glasgow and Clyde
University of Glasgow

Active, not recruiting

EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction (EMPRESS-MI)

Myocardial Infarction

United Kingdom
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Active, not recruiting

Empagliflozin and Hepatic Glucose Metabolism

Hepatic Glucose Metabolism

United States
Centre Hospitalier Universitaire Vaudois

Completed

Empagliflozin and Renal Oxygenation in Healthy Volunteers (EMPA-REIN)

Nephropathy

Switzerland
UCB Pharma SA

Completed

Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy

Generalized Epilepsy
Organon and Co

Completed

A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3)

Hypertension
Astellas Pharma Europe B.V.

Completed

Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms (Neptune)

Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia

Belgium, Italy, France, Austria, United Kingdom, Netherlands, Hungary, Russian Federation, Poland, Slovakia, Czech Republic, Belarus, Germany
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

Diabetes Mellitus, Type 2

United States, Ukraine, Argentina, Mexico, Romania, South Africa, Korea, Republic of, Russian Federation, Brazil, Puerto Rico, Hungary, Slovakia, Czechia
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)

Urinary Tract Infections | Pyelonephritis
Bernhard Nocht Institute for Tropical Medicine
German Federal Ministry of Education and Research; Deutscher Akademischer Austausch... and other collaborators

Completed

Intermittent Treatment With Sulfadoxine-pyrimethamine for Malaria Control in Infants

Anemia | Malaria

Ghana
Ranbaxy Laboratories Limited

Completed

A Comparitive Bioavailability Study of Metformin Hydrochloride Liquid 500mg/ 5 mL Under Fasting Conditions and After Low and High Fat Meal

Healthy
Conatus Pharmaceuticals Inc.

Completed

Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis (ENCORE-NF)

Liver Diseases | Fibrosis | Non-alcoholic Steatohepatitis

United States, Spain, Germany
Tianjin Hemay Pharmaceutical Co., Ltd

Completed

A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

China

Search clinical trials for: 12.5 mg empagliflozin/850 mg metformin FDC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations